Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation

American Journal of Cardiology

Volumn 110, Issue 5, 2012, Pages 673-677

  Fragakis, Nikolaos ^a   Koskinas, Konstantinos C ^a   Katritsis, Demosthenes G ^b   Pagourelias, Efstathios D ^a   Zografos, Theodoros ^b   Geleris, Paraschos ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b Athens Euroclinic   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; RANOLAZINE;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL DIAMETER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ACETANILIDES; ADMINISTRATION, ORAL; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84864953997     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.04.044     Document Type: Article

References (30)

1. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, S. Ernst, I.C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S.H. Hohloser, P. Kolh, J.Y. Le Heuzey, P. Ponikowski, F.H. Rutten Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
2. I. Savelieva, J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace 10 2008 647 655
3. G.E. Kochiadakis, N.E. Igoumenidis, M.E. Hamilos, M.E. Marketou, G.I. Chlouverakis, P.E. Vardas A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation Am J Cardiol 99 2007 1721 1725
4. P.E. Vardas, G.E. Kochiadakis, N.E. Igoumenidis, A.M. Tsatsakis, E.N. Simantirakis, G.I. Chlouverakis Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study Chest 117 2000 1538 1545
5. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt, A. Burashnikov, J.M. Di Diego, J.M. Fish, J.M. Cordeiro, G. Thomas Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904 910
6. P.H. Stone Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias Cardiol Clin 26 2008 603 614
7. B.M. Scirica, D.A. Morrow, H. Hod, S.A. Murphy, L. Belardinelli, C.M. Hedgepeth, P. Molhoek, F.W. Verheugt, B.J. Gersh, C.H. McCabe, E. Braunwald Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis In Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652
8. R.H. Miles, R. Passman, D.K. Murdock Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting Am J Cardiol 108 2011 673 676
9. S. Sicouri, A. Burashnikov, L. Belardinelli, C. Antzelevitch Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria Circ Arrhythm Electrophysiol 3 2010 88 95
10. A. Burashnikov, S. Sicouri, J.M. Di Diego, L. Belardinelli, C. Antzelevitch Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation J Am Coll Cardiol 56 2010 1216 1224
11. P. Chevalier, A. Durand-Dubief, H. Burri, M. Cucherat, G. Kirkorian, P. Touboul Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis J Am Coll Cardiol 41 2003 255 262
12. Ranexa prescribing information http://www.ranexa.com/global/Prescribing- Information.aspx Accessed April 23, 2012
13. L.B. Mitchell, D.G. Wyse, A.M. Gillis, H.J. Duff Electropharmacology of amiodarone therapy initiation Time courses of onset of electrophysiologic and antiarrhythmic effects Circulation 80 1989 34 42
14. P.R. Kowey, R.A. Marinchak, S.J. Rials, R.A. Filart Acute treatment of atrial fibrillation Am J Cardiol 81 suppl 1998 16C 22C
15. S. Sossalla, B. Kallmeyer, S. Wagner, M. Mazur, U. Maurer, K. Toischer, J.D. Schmitto, R. Seipelt, F.A. Schöndube, G. Hasenfuss, L. Belardinelli, L.S. Maier Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium J Am Coll Cardiol 55 2010 2330 2342
16. S. Sicouri, A. Glass, L. Belardinelli, C. Antzelevitch Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations Heart Rhythm 5 2008 1019 1026
17. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, C. Antzelevitch Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457
18. K. Kumar, B.D. Nearing, M. Carvas, B.C. Nascimento, M. Acar, L. Belardinelli, R.L. Verrier Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart J Cardiovasc Electrophysiol 20 2009 796 802
19. I. Kodama, K. Kamiya, J. Toyama Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent Am J Cardiol 84 suppl 1999 20R 28R
20. A.C. Zygmunt, V.V. Nesterenko, S. Rajamani, D. Hu, H. Baras-Martinez, L. Belardinelli, C. Antzelevitch Mechanisms of atrial-selective block of Na+ channels by ranolazine: I Experimental analysis of the use-dependent block Am J Physiol Heart Circ Physiol 301 2011 H1606 H1614
21. Y.K. Iwasaki, K. Nishida, T. Kato, S. Nattel Atrial fibrillation pathophysiology: implications for management Circulation 124 2011 2264 2274
22. D.K. Murdock, M. Kersten, J. Kaliebe, G. Larrain The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation Indian Pacing Electrophysiol J 9 2009 260 267
23. D.K. Murdock, J.A. Reiffel, J. Kaliebe, G. Larrain The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for a new "pill-in-pocket" approach in structural heart disease J Atr Fibrillation 2 2010 705 710
24. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
25. L. Wu, J. Ma, H. Li, C. Wang, E. Grandi, P. Zhang, A. Luo, D.M. Bers, J.C. Shryock, L. Belardinelli Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization Circulation 123 2011 1713 1720
26. P.M. Orth, J.C. Hesketh, C.K. Mak, Y. Yang, S. Lin, G.N. Beatch, A.M. Ezrin, D. Fedida Rsd1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents Cardiovasc Res 70 2006 486 496
27. M.J. Koren, M.R. Crager, M. Sweeney Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE) J Am Coll Cardiol 49 2007 1027 1034
28. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, S.A. Murphy, A. Budaj, S. Varshavsky, A.A. Wolff, A. Skene, C.H. McCabe, E. Braunwald MERLIN-TIMI 36 Trial Investigators Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
29. P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, L. Meng ERICA Investigators Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial J Am Coll Cardiol 48 2006 566 575
30. European Medicines Agency European public assessment report for Ranexa http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000805/WC500045940.pdf Accessed April 23, 2012